Brief: ARCA Biopharma Provides Update On ASPEN-COVID-19 Phase 2B Clinical Trial

Oruka Therapeutics

13/07/2021 13:15

July 13 (Reuters) - ARCA Biopharma Inc  ABIO.O :
    * ARCA BIOPHARMA PROVIDES UPDATE ON ASPEN-COVID-19 PHASE 2B
CLINICAL TRIAL EVALUATING RNAPC2 AS A POTENTIAL TREATMENT FOR
COVID-19
    * ARCA BIOPHARMA INC - TRIAL EXPANDED TO SOUTH AMERICA, WITH
REGULATORY APPROVALS FOR ARGENTINA AND BRAZIL
    * ARCA BIOPHARMA INC - RNAPC2 DEVELOPMENT FOCUSED ON UNMET
NEED
FOR TREATMENTS IN HOSPITALIZED COVID-19 PATIENTS
    * ARCA BIOPHARMA INC - TARGET TRIAL ENROLLMENT INCREASED TO
160
PATIENTS
    * ARCA BIOPHARMA INC - TOPLINE TRIAL DATA ANTICIPATED IN Q4
OF
2021

Source text for Eikon:  ID:nGNX98qPKF 
Further company coverage:  ABIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))